Training
- Specialist in Ophthalmology at Hospital Universitario Gregorio Marañón Madrid, since February 1992, as a member of the oculomotor section.
- Member of the Directive Staff of the Spanish Society of Strabismus and pediatric Ophthalmology
- President of the Spanish Society of Strabismus and pediatric Ophthalmology
Clinical and Surgical experience:
-
Cataract surgery
-
Strabismus and diplopia surgery with general, topical and local aenesthesia
-
Botox for strabismus treatment
-
Opthalmological pediatric surgery
-
Diagnosis of strabismus and neuro-ophthalmological pathology
-
Diagnosis and treatment of nystagmus
-
Diagnosis and treatment of subjects with autism spectrum disorder
-
Diagnosis and treatment of children with rare diseases
-
Diagnosis and treatment of children with cortical visual impairment
-
Visual rehabilitation of patients with congenital glaucoma, strabismus and congenital cataract
-
Diagnosis and treatment of diplopia
Publications and meetings
- Author and co-author of many publications in International and Spanish Ophthalmology Journals: 124
- Author of books and different chapters in ophthalmology books: 27
-
Presentations presented at international and national scientific meetings: 342
-
Meeting assistance: 287
-
Speaker and chief moderator in several round tables and symposium in national and international meetings related to Opthalmology and Strabismus and Pediatric Ophthalmology
-
Ophthalmology Meeting organitations related to Strabismus and Pediatric Ophthalmology
-
Editorial board member of several scientific journals
-
Editor of the official journal of the Spanish Strabismus and ophthalmology pediatric society: Acta Estrabológica
- Associate editor of the journal of Spanish Society of Ophthalmology
-
Editor of REOP: journal of Strabismus and Opthalmology pediatric
-
Reviewer of several ophthalmology journals
-
Awards for videos, posters and oral communications: 16
-
Member of several research trials:
-
Oncology Clinical Protocol CDRB436G2201 Phase II open-labelglobal study to evaluate the effect of dabrafenib in combinationwith trametinib in children and adolescent patients with BRAF V600 mutation positive low grade Glioma (LGG)or relapsed or refractory High Grade Glioma (HGG)
-
CSEG101B2201: a phase 2, Multicenter, Open-Label Study to assess appropriate dosing and to evaluate safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age groups ofPediatric Sickle Cell Disease Patiens with Vaso-Occlusive Crisis
-
A Phase I/II, Single-Arm, Open-label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥ 1 to < 7 Years with Neurofibromatosis Type 1 (NF1) Related to Symptomatic, Inoperable Plexiform Neurofibromas (PN) (SPRINKLE)
-